Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 51, Issue 10, Pages 1376-1402
Publisher
Wiley
Online
2011-01-06
DOI
10.1177/0091270010387428
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir with and without Maraviroc Coadministration
- (2010) Silvia Baroncelli et al. ANNALS OF PHARMACOTHERAPY
- Minimal Removal of Raltegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease
- (2010) J. Molto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients
- (2010) Rob Ter Heine et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Obesity on the Pharmacokinetics of Drugs in Humans
- (2010) Michael J. Hanley et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis
- (2009) Pierre Giguère et al. AIDS
- Etravirine–raltegravir, a marked interaction in HIV-1-infected patients: about four cases
- (2009) Amélie Ménard et al. AIDS
- Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis
- (2009) David M Burger et al. AIDS
- Update on Rifampin and Rifabutin Drug Interactions
- (2009) Anne M. Baciewicz et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Safety and Efficacy of Raltegravir in HIV-Infected Transplant Patients Cotreated with Immunosuppressive Drugs
- (2009) L. Tricot et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics
- (2009) M. Iwamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir
- (2009) W. D. Hanley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected Subjects
- (2009) G. Moyle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- High Concentration of Raltegravir in Semen of HIV-Infected Men: Results from a Substudy of the EASIER-ANRS 138 Trial
- (2009) C. Barau et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir
- (2009) L. A. Wenning et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of Omeprazole on Plasma Levels of Raltegravir
- (2009) Marian Iwamoto et al. CLINICAL INFECTIOUS DISEASES
- High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial
- (2009) Y. Yazdanpanah et al. CLINICAL INFECTIOUS DISEASES
- Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action
- (2009) Caroline Bazzoli et al. CLINICAL PHARMACOKINETICS
- Drug Uptake Systems in Liver and Kidney: A Historic Perspective
- (2009) B Hagenbuch CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms
- (2009) LA Wenning et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection
- (2009) Martin Markowitz et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient
- (2009) A. Di Biagio et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation
- (2009) A. Turkova et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Effect of Raltegravir on the Glucuronidation of Lamotrigine
- (2009) Matthijs van Luin et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
- (2009) Aylin Yilmaz et al. PLoS One
- Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects
- (2008) M. S. Anderson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
- (2008) M. Iwamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lack of a Significant Drug Interaction between Raltegravir and Tenofovir
- (2008) L. A. Wenning et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects
- (2008) Marian Iwamoto et al. CLINICAL INFECTIOUS DISEASES
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation
- (2007) Marian Iwamoto et al. JOURNAL OF CLINICAL PHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started